Medically reviewed by Veronica Hackethal | MD, MSc , Harvard University | University of Oxford | Columbia Vagelos College of Physicians and Surgeons on March 26th, 2026
If you observe any changes in skin color, irritation, or discomfort, change the injection site
Vedtofte L, Bahne E, Foghsgaard S, Bagger JI, Andreasen C, Strandberg C, et al
Note on Phase 3 Doses Versus Phase 2 The Phase 3 TRIUMPH-4 design used three maintenance doses: 4mg, 9mg, and 12mg
What is GLP-1 Microdosing
This issue has been attributed to the mode of action of these antagonists: those blocking CAP-, proton-, and heat-induced TRPV1 activation result in hyperthermia, whereas those sparing proton-induced activation do not lead to hyperthermia 33,35